Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05409066




Registration number
NCT05409066
Ethics application status
Date submitted
3/06/2022
Date registered
8/06/2022
Date last updated
4/06/2024

Titles & IDs
Public title
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Scientific title
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Secondary ID [1] 0 0
2021-000169-34
Secondary ID [2] 0 0
M20-638
Universal Trial Number (UTN)
Trial acronym
EPCORE FL-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma (FL) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Epcoritamab
Treatment: Drugs - Rituximab
Treatment: Drugs - Lenalidomide

Experimental: Epcoritamab Dose A in Combination With R2 - Participants will receive epcoritamab Dose A in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).

Experimental: Epcoritamab Dose B in Combination With R2 - Participants will receive epcoritamab Dose B in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days). Enrollment is closed for this arm.

Active Comparator: Lenalidomide and Rituximab (R2) - Participants will receive lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).


Treatment: Drugs: Epcoritamab
Subcutaneous Injection

Treatment: Drugs: Rituximab
Intravenous Infusion

Treatment: Drugs: Lenalidomide
Oral Capsules
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS)
Timepoint [1] 0 0
Up to approximately 5 years
Secondary outcome [1] 0 0
Percentage of Participants Achieving Complete Response (CR)
Timepoint [1] 0 0
Up to approximately 5 years
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to approximately 8 years from randomization
Secondary outcome [3] 0 0
Percentage of Participants Achieving Minimal Residual Disease (MRD) Negativity
Timepoint [3] 0 0
Up to approximately 5 years

Eligibility
Key inclusion criteria
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 to 2.

- Participant has:

- Fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating
positive lesion compatible with computed tomography (CT) or magnetic resonance
image (MRI)-defined anatomical tumor sites AND

- >= 1 measurable nodal lesion (long axis > 1.5 cm) or >= 1 measurable extra-nodal
lesion (long axis > 1.0 cm) on CT scan or MRI.

- Histologically confirmed classic follicular lymphoma (FL) [previously Grade 1 to 3a
FL] stage II, III, or IV with no evidence of histologic transformation to an
aggressive lymphoma and CD20+ disease on most recent representative tumor biopsy based
on the pathology report.

- Relapsed or refractory (R/R) disease to at least one prior systemic regimen that
contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy.
(Participant who received only prior anti-CD20 mAb monotherapy and/or radiation
therapy is not eligible.)

- Eligible to receive R2 per investigator determination.

- Estimated Creatinine Clearance (CrCl) >= 50 mL/min.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Documented refractoriness to lenalidomide.

- Have lenalidomide exposure within 12 months prior to randomization.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/09/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
16/06/2030
Actual
Sample size
Target
500
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital /ID# 239272 - Camperdown
Recruitment hospital [2] 0 0
Nepean Hospital /ID# 239093 - Kingswood
Recruitment hospital [3] 0 0
Townsville University Hospital /ID# 231124 - Douglas
Recruitment hospital [4] 0 0
Peninsula Private Hospital /ID# 238796 - Frankston
Recruitment hospital [5] 0 0
Fiona Stanley Hospital /ID# 231122 - Murdoch
Recruitment hospital [6] 0 0
Hollywood Medical Centre /ID# 251789 - Nedlands
Recruitment hospital [7] 0 0
Royal Perth Hospital /ID# 230456 - Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2747 - Kingswood
Recruitment postcode(s) [3] 0 0
4814 - Douglas
Recruitment postcode(s) [4] 0 0
3199 - Frankston
Recruitment postcode(s) [5] 0 0
6150 - Murdoch
Recruitment postcode(s) [6] 0 0
6009 - Nedlands
Recruitment postcode(s) [7] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
Montana
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
Argentina
State/province [10] 0 0
Ciudad Autonoma De Buenos Aires
Country [11] 0 0
Argentina
State/province [11] 0 0
Cordoba
Country [12] 0 0
Argentina
State/province [12] 0 0
Santa Fe
Country [13] 0 0
Austria
State/province [13] 0 0
Niederoesterreich
Country [14] 0 0
Austria
State/province [14] 0 0
Oberoesterreich
Country [15] 0 0
Austria
State/province [15] 0 0
Salzburg
Country [16] 0 0
Belgium
State/province [16] 0 0
Antwerpen
Country [17] 0 0
Belgium
State/province [17] 0 0
Hainaut
Country [18] 0 0
Belgium
State/province [18] 0 0
Oost-Vlaanderen
Country [19] 0 0
Belgium
State/province [19] 0 0
Vlaams-Brabant
Country [20] 0 0
Belgium
State/province [20] 0 0
Anderlecht
Country [21] 0 0
Belgium
State/province [21] 0 0
Liege
Country [22] 0 0
Belgium
State/province [22] 0 0
Turnhout
Country [23] 0 0
Brazil
State/province [23] 0 0
Parana
Country [24] 0 0
Brazil
State/province [24] 0 0
Sao Paulo
Country [25] 0 0
Brazil
State/province [25] 0 0
Rio de Janeiro
Country [26] 0 0
Canada
State/province [26] 0 0
Alberta
Country [27] 0 0
Canada
State/province [27] 0 0
British Columbia
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
China
State/province [29] 0 0
Beijing
Country [30] 0 0
China
State/province [30] 0 0
Fujian
Country [31] 0 0
China
State/province [31] 0 0
Guangdong
Country [32] 0 0
China
State/province [32] 0 0
Henan
Country [33] 0 0
China
State/province [33] 0 0
Hubei
Country [34] 0 0
China
State/province [34] 0 0
Jiangsu
Country [35] 0 0
China
State/province [35] 0 0
Jiangxi
Country [36] 0 0
China
State/province [36] 0 0
Liaoning
Country [37] 0 0
China
State/province [37] 0 0
Shaanxi
Country [38] 0 0
China
State/province [38] 0 0
Shanghai
Country [39] 0 0
China
State/province [39] 0 0
Tianjin
Country [40] 0 0
China
State/province [40] 0 0
Zhejiang
Country [41] 0 0
Czechia
State/province [41] 0 0
Hradec Kralove
Country [42] 0 0
Czechia
State/province [42] 0 0
Prague
Country [43] 0 0
Czechia
State/province [43] 0 0
Praha
Country [44] 0 0
Denmark
State/province [44] 0 0
Midtjylland
Country [45] 0 0
Denmark
State/province [45] 0 0
Syddanmark
Country [46] 0 0
France
State/province [46] 0 0
Auvergne-Rhone-Alpes
Country [47] 0 0
France
State/province [47] 0 0
Bretagne
Country [48] 0 0
France
State/province [48] 0 0
Cote-d Or
Country [49] 0 0
France
State/province [49] 0 0
Franche-Comte
Country [50] 0 0
France
State/province [50] 0 0
Gard
Country [51] 0 0
France
State/province [51] 0 0
Gironde
Country [52] 0 0
France
State/province [52] 0 0
Marne
Country [53] 0 0
France
State/province [53] 0 0
Meurthe-et-Moselle
Country [54] 0 0
France
State/province [54] 0 0
Nord
Country [55] 0 0
France
State/province [55] 0 0
Paris
Country [56] 0 0
France
State/province [56] 0 0
Pays-de-la-Loire
Country [57] 0 0
France
State/province [57] 0 0
Rhone
Country [58] 0 0
France
State/province [58] 0 0
Vendee
Country [59] 0 0
France
State/province [59] 0 0
Vienne
Country [60] 0 0
France
State/province [60] 0 0
Caen
Country [61] 0 0
France
State/province [61] 0 0
Toulouse Cedex 9
Country [62] 0 0
Germany
State/province [62] 0 0
Baden-Wuerttemberg
Country [63] 0 0
Germany
State/province [63] 0 0
Hessen
Country [64] 0 0
Germany
State/province [64] 0 0
Sachsen
Country [65] 0 0
Germany
State/province [65] 0 0
Thueringen
Country [66] 0 0
Germany
State/province [66] 0 0
Bamberg
Country [67] 0 0
Germany
State/province [67] 0 0
Berlin
Country [68] 0 0
Germany
State/province [68] 0 0
Bonn
Country [69] 0 0
Germany
State/province [69] 0 0
Dresden
Country [70] 0 0
Germany
State/province [70] 0 0
Essen
Country [71] 0 0
Germany
State/province [71] 0 0
Goettingen
Country [72] 0 0
Germany
State/province [72] 0 0
Magdeburg
Country [73] 0 0
Germany
State/province [73] 0 0
Trier
Country [74] 0 0
Germany
State/province [74] 0 0
Wuerzburg
Country [75] 0 0
Greece
State/province [75] 0 0
Attiki
Country [76] 0 0
Greece
State/province [76] 0 0
Athens
Country [77] 0 0
Greece
State/province [77] 0 0
Ioannina
Country [78] 0 0
Greece
State/province [78] 0 0
Thessaloniki
Country [79] 0 0
Hungary
State/province [79] 0 0
Hajdu-Bihar
Country [80] 0 0
Hungary
State/province [80] 0 0
Somogy
Country [81] 0 0
Hungary
State/province [81] 0 0
Szabolcs-Szatmar-Bereg
Country [82] 0 0
Hungary
State/province [82] 0 0
Vas
Country [83] 0 0
Hungary
State/province [83] 0 0
Budapest
Country [84] 0 0
Hungary
State/province [84] 0 0
Szeged
Country [85] 0 0
Israel
State/province [85] 0 0
H_efa
Country [86] 0 0
Israel
State/province [86] 0 0
HaMerkaz
Country [87] 0 0
Israel
State/province [87] 0 0
HaTsafon
Country [88] 0 0
Israel
State/province [88] 0 0
Tel-Aviv
Country [89] 0 0
Israel
State/province [89] 0 0
Yerushalayim
Country [90] 0 0
Israel
State/province [90] 0 0
Haifa
Country [91] 0 0
Italy
State/province [91] 0 0
Foggia
Country [92] 0 0
Italy
State/province [92] 0 0
Lazio
Country [93] 0 0
Italy
State/province [93] 0 0
Milano
Country [94] 0 0
Italy
State/province [94] 0 0
Piemonte
Country [95] 0 0
Italy
State/province [95] 0 0
Torino
Country [96] 0 0
Italy
State/province [96] 0 0
Alessandria
Country [97] 0 0
Italy
State/province [97] 0 0
Aviano
Country [98] 0 0
Italy
State/province [98] 0 0
Bari
Country [99] 0 0
Italy
State/province [99] 0 0
Brescia
Country [100] 0 0
Italy
State/province [100] 0 0
Napoli
Country [101] 0 0
Italy
State/province [101] 0 0
Novara
Country [102] 0 0
Italy
State/province [102] 0 0
Palermo
Country [103] 0 0
Italy
State/province [103] 0 0
Ravenna
Country [104] 0 0
Japan
State/province [104] 0 0
Aichi
Country [105] 0 0
Japan
State/province [105] 0 0
Chiba
Country [106] 0 0
Japan
State/province [106] 0 0
Ehime
Country [107] 0 0
Japan
State/province [107] 0 0
Fukuoka
Country [108] 0 0
Japan
State/province [108] 0 0
Fukushima
Country [109] 0 0
Japan
State/province [109] 0 0
Hokkaido
Country [110] 0 0
Japan
State/province [110] 0 0
Hyogo
Country [111] 0 0
Japan
State/province [111] 0 0
Kagoshima
Country [112] 0 0
Japan
State/province [112] 0 0
Kanagawa
Country [113] 0 0
Japan
State/province [113] 0 0
Kyoto
Country [114] 0 0
Japan
State/province [114] 0 0
Mie
Country [115] 0 0
Japan
State/province [115] 0 0
Miyagi
Country [116] 0 0
Japan
State/province [116] 0 0
Nagano
Country [117] 0 0
Japan
State/province [117] 0 0
Osaka
Country [118] 0 0
Japan
State/province [118] 0 0
Tokyo
Country [119] 0 0
Japan
State/province [119] 0 0
Yamagata
Country [120] 0 0
Japan
State/province [120] 0 0
Yamanashi
Country [121] 0 0
Japan
State/province [121] 0 0
Okayama
Country [122] 0 0
Korea, Republic of
State/province [122] 0 0
Busan Gwang Yeogsi
Country [123] 0 0
Korea, Republic of
State/province [123] 0 0
Gyeonggido
Country [124] 0 0
Korea, Republic of
State/province [124] 0 0
Gyeongsangbugdo
Country [125] 0 0
Korea, Republic of
State/province [125] 0 0
Gyeongsangnamdo
Country [126] 0 0
Korea, Republic of
State/province [126] 0 0
Jeonrabugdo
Country [127] 0 0
Korea, Republic of
State/province [127] 0 0
Seoul Teugbyeolsi
Country [128] 0 0
Korea, Republic of
State/province [128] 0 0
Busan
Country [129] 0 0
Korea, Republic of
State/province [129] 0 0
Seoul
Country [130] 0 0
Netherlands
State/province [130] 0 0
Noord-Brabant
Country [131] 0 0
Netherlands
State/province [131] 0 0
Noord-Holland
Country [132] 0 0
Netherlands
State/province [132] 0 0
Zuid-Holland
Country [133] 0 0
Netherlands
State/province [133] 0 0
Amsterdam
Country [134] 0 0
Netherlands
State/province [134] 0 0
Deventer
Country [135] 0 0
Netherlands
State/province [135] 0 0
Enschede
Country [136] 0 0
Netherlands
State/province [136] 0 0
Goes
Country [137] 0 0
Netherlands
State/province [137] 0 0
Groningen
Country [138] 0 0
Netherlands
State/province [138] 0 0
Leiden
Country [139] 0 0
Netherlands
State/province [139] 0 0
Nieuwegein
Country [140] 0 0
Netherlands
State/province [140] 0 0
Nijmegen
Country [141] 0 0
New Zealand
State/province [141] 0 0
Auckland
Country [142] 0 0
New Zealand
State/province [142] 0 0
Manawatu-Wanganui
Country [143] 0 0
Poland
State/province [143] 0 0
Pomorskie
Country [144] 0 0
Poland
State/province [144] 0 0
Swietokrzyskie
Country [145] 0 0
Poland
State/province [145] 0 0
Wielkopolskie
Country [146] 0 0
Poland
State/province [146] 0 0
Cracow
Country [147] 0 0
Puerto Rico
State/province [147] 0 0
Rio Piedras
Country [148] 0 0
Slovakia
State/province [148] 0 0
Bratislavsky Kraj
Country [149] 0 0
South Africa
State/province [149] 0 0
Gauteng
Country [150] 0 0
South Africa
State/province [150] 0 0
Western Cape
Country [151] 0 0
Spain
State/province [151] 0 0
Barcelona
Country [152] 0 0
Spain
State/province [152] 0 0
Cantabria
Country [153] 0 0
Spain
State/province [153] 0 0
Cordoba
Country [154] 0 0
Spain
State/province [154] 0 0
Navarra
Country [155] 0 0
Spain
State/province [155] 0 0
Caceres
Country [156] 0 0
Spain
State/province [156] 0 0
Madrid
Country [157] 0 0
Spain
State/province [157] 0 0
Salamanca
Country [158] 0 0
Spain
State/province [158] 0 0
Sevilla
Country [159] 0 0
Sweden
State/province [159] 0 0
Norrbottens Lan
Country [160] 0 0
Sweden
State/province [160] 0 0
Vastra Gotalands Lan
Country [161] 0 0
Sweden
State/province [161] 0 0
Linkoping
Country [162] 0 0
Switzerland
State/province [162] 0 0
Aargau
Country [163] 0 0
Switzerland
State/province [163] 0 0
Graubuenden
Country [164] 0 0
Switzerland
State/province [164] 0 0
Sankt Gallen
Country [165] 0 0
Switzerland
State/province [165] 0 0
Ticino
Country [166] 0 0
Taiwan
State/province [166] 0 0
Kaohsiung
Country [167] 0 0
Taiwan
State/province [167] 0 0
Taichung
Country [168] 0 0
Taiwan
State/province [168] 0 0
Tainan
Country [169] 0 0
Turkey
State/province [169] 0 0
Ankara
Country [170] 0 0
Turkey
State/province [170] 0 0
Antalya
Country [171] 0 0
Turkey
State/province [171] 0 0
Diyarbakir
Country [172] 0 0
Turkey
State/province [172] 0 0
Istanbul
Country [173] 0 0
Turkey
State/province [173] 0 0
Izmir
Country [174] 0 0
Turkey
State/province [174] 0 0
Kocaeli
Country [175] 0 0
Turkey
State/province [175] 0 0
Samsun
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Devon
Country [177] 0 0
United Kingdom
State/province [177] 0 0
London, City Of
Country [178] 0 0
United Kingdom
State/province [178] 0 0
Oxfordshire
Country [179] 0 0
United Kingdom
State/province [179] 0 0
Scotland
Country [180] 0 0
United Kingdom
State/province [180] 0 0
Birmingham
Country [181] 0 0
United Kingdom
State/province [181] 0 0
Colchester
Country [182] 0 0
United Kingdom
State/province [182] 0 0
Leeds
Country [183] 0 0
United Kingdom
State/province [183] 0 0
Liverpool
Country [184] 0 0
United Kingdom
State/province [184] 0 0
Manchester
Country [185] 0 0
United Kingdom
State/province [185] 0 0
Newcastle upon Tyne
Country [186] 0 0
United Kingdom
State/province [186] 0 0
Portsmouth

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Genmab
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
AbbVie
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of
cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment
and the disease recurs in almost all patients. This study will assess how safe and effective
epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult
participants with relapsed or refractory (R/R) FL. Adverse events and change in disease
condition will be assessed.

Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors
put the participants in 1 of 3 groups, called treatment arms. Each group receives a different
treatment. Enrollment to one of the groups is closed. Around 500 adult participants with R/R
FL will be enrolled in approximately 300 sites across the world.

Participants will receive R2 (375 mg/m^2 intravenous infusion of rituximab up to 5 cycles and
oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combination with
subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days).

There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects and completing questionnaires.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05409066
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
ABBVIE CALL CENTER
Address 0 0
Country 0 0
Phone 0 0
844-663-3742
Fax 0 0
Email 0 0
abbvieclinicaltrials@abbvie.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05409066